The drug discovery research for lecanemab awarded the 9th Bioindustry Award by the Japan Bioindustry Association

Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. BioArctic has the right to commercialize Leqembi in the Nordic region together with Eisai and the two companies are preparing for a joint commercialization in the region. Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen...

Eisai serves as the lead of lecanemab development and regulatory submissions globally with both Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority. BioArctic has the right to commercialize Leqembi in the Nordic region together with Eisai and the two companies are preparing for a joint commercialization in the region.

The information was released for public disclosure, through the agency of the contact person below, on July 16, 2025, at 9:30 a.m. CET.

For further information, please contact: 
Oskar Bosson, VP Communications and IR
E-mail: [email protected]
Phone: +46 70 410 71 80 

About BioArctic AB

BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company is the originator of Leqembi® (lecanemab) - the world's first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer's disease. Leqembi has been developed together with Eisai. BioArctic has a broad research portfolio within Alzheimer's disease, Parkinson's disease, ALS and enzyme deficiency diseases. Several of the projects utilize the company's proprietary BrainTransporter™ technology, which improves the transport of drugs into the brain. BioArctic's B share (BIOA B) is listed on Nasdaq Stockholm Large Cap. For more information, please visit www.bioarctic.com.

This information was brought to you by Cision http://news.cision.com.

https://news.cision.com/bioarctic/r/the-drug-discovery-research-for-lecanemab-awarded-the-9th-bioindustry-award-by-the-japan-bioindustry,c4207689

The following files are available for download:

 

View original content:https://www.prnewswire.co.uk/news-releases/the-drug-discovery-research-for-lecanemab-awarded-the-9th-bioindustry-award-by-the-japan-bioindustry-association-302506575.html